Standard dose
Sponsors
University of Calgary, Universitaire Ziekenhuizen KU Leuven, Tata Medical Center, Hospital Ana Nery, Medical University of Graz
Conditions
Head and Neck CancerHeart FailureMalignant Neoplasm of Hypopharynx Stage IIIMalignant Neoplasm of Hypopharynx Stage IVaMalignant Neoplasm of Hypopharynx Stage IVbMalignant Neoplasm of Larynx Stage IIIMalignant Neoplasm of Larynx Stage IVMalignant Neoplasm of Oropharynx Stage III
Phase 2
Intensive Versus Conventional Digoxin Use in Patients With Heart Failure
NCT02797145
Start: 2016-05-31End: 2018-06-30Target: 200Updated: 2016-06-13
Multimodality- Adapted Dose Modification in Head and Neck Cancer Radiation Therapy 
NCT04933357
Start: 2019-09-16End: 2022-09-30Target: 75Updated: 2021-06-21
Phase 3
Unknown Phase
Fathers and Late Preterm Babies Study
CompletedNCT01056653
Start: 2008-12-31End: 2013-01-31Updated: 2017-03-29
Dose Escalation Versus Standard in Laryngopharyngeal Cancers
CompletedNCT02757222
Start: 2016-01-31End: 2022-12-31Updated: 2023-12-28
Comparison of Contrast Agent Administration Protocols
CompletedNCT04300972
Start: 2016-06-15End: 2016-10-15Updated: 2020-03-09